JP2024501246A5 - - Google Patents
Info
- Publication number
- JP2024501246A5 JP2024501246A5 JP2023537946A JP2023537946A JP2024501246A5 JP 2024501246 A5 JP2024501246 A5 JP 2024501246A5 JP 2023537946 A JP2023537946 A JP 2023537946A JP 2023537946 A JP2023537946 A JP 2023537946A JP 2024501246 A5 JP2024501246 A5 JP 2024501246A5
- Authority
- JP
- Japan
- Prior art keywords
- chr16
- cells
- cell
- manipulated
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130098P | 2020-12-23 | 2020-12-23 | |
| US63/130,098 | 2020-12-23 | ||
| US202163251002P | 2021-09-30 | 2021-09-30 | |
| US63/251,002 | 2021-09-30 | ||
| US202163254971P | 2021-10-12 | 2021-10-12 | |
| US63/254,971 | 2021-10-12 | ||
| US202163288502P | 2021-12-10 | 2021-12-10 | |
| US63/288,502 | 2021-12-10 | ||
| PCT/US2021/064933 WO2022140587A1 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for genetically modifying ciita in a cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501246A JP2024501246A (ja) | 2024-01-11 |
| JP2024501246A5 true JP2024501246A5 (enExample) | 2025-09-02 |
Family
ID=80445732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537946A Pending JP2024501246A (ja) | 2020-12-23 | 2021-12-22 | 細胞中のｃｉｉｔａを遺伝子修飾するための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240139323A1 (enExample) |
| EP (1) | EP4267723A1 (enExample) |
| JP (1) | JP2024501246A (enExample) |
| KR (1) | KR20230135068A (enExample) |
| AU (1) | AU2021410751A1 (enExample) |
| BR (1) | BR112023012432A2 (enExample) |
| CA (1) | CA3205042A1 (enExample) |
| CL (2) | CL2023001855A1 (enExample) |
| CO (1) | CO2023009613A2 (enExample) |
| CR (1) | CR20230321A (enExample) |
| IL (1) | IL303970A (enExample) |
| MX (1) | MX2023007465A (enExample) |
| TW (1) | TW202242101A (enExample) |
| WO (1) | WO2022140587A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116042676A (zh) * | 2023-01-04 | 2023-05-02 | 上海南方模式生物科技股份有限公司 | 一种基于CRISPR-Cas9构建TNF-α-HiBit动物模型的方法 |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049631A1 (en) * | 2023-08-28 | 2025-03-06 | Kyverna Therapeutics, Inc. | Allogeneic car-t cell therapies and manufacture thereof |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| CN105683376A (zh) * | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| EP3724326A1 (en) * | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AU2019282824C1 (en) | 2018-06-08 | 2026-04-23 | Intellia Therapeutics, Inc. | Modified guide RNAS for gene editing |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| IL282267B2 (en) | 2018-10-15 | 2026-03-01 | Univ Massachusetts | Programmed DNA editing by chimeric deaminase-nme2cas9 proteins |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| KR20210128440A (ko) * | 2019-02-15 | 2021-10-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 범용 공여자 줄기 세포 및 관련 방법 |
| CA3142947A1 (en) * | 2019-06-12 | 2020-12-17 | The Regents Of The University Of California | Engineered off-the-shelf immune cells and methods of use thereof |
| CN114457034A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-1阻断物的多能干细胞衍生物及其应用 |
-
2021
- 2021-12-22 WO PCT/US2021/064933 patent/WO2022140587A1/en not_active Ceased
- 2021-12-22 TW TW110148207A patent/TW202242101A/zh unknown
- 2021-12-22 AU AU2021410751A patent/AU2021410751A1/en active Pending
- 2021-12-22 CA CA3205042A patent/CA3205042A1/en active Pending
- 2021-12-22 MX MX2023007465A patent/MX2023007465A/es unknown
- 2021-12-22 JP JP2023537946A patent/JP2024501246A/ja active Pending
- 2021-12-22 BR BR112023012432A patent/BR112023012432A2/pt unknown
- 2021-12-22 IL IL303970A patent/IL303970A/en unknown
- 2021-12-22 KR KR1020237024498A patent/KR20230135068A/ko active Pending
- 2021-12-22 EP EP21854910.3A patent/EP4267723A1/en active Pending
- 2021-12-22 CR CR20230321A patent/CR20230321A/es unknown
-
2023
- 2023-06-20 CL CL2023001855A patent/CL2023001855A1/es unknown
- 2023-06-22 US US18/339,930 patent/US20240139323A1/en active Pending
- 2023-07-19 CO CONC2023/0009613A patent/CO2023009613A2/es unknown
- 2023-10-17 CL CL2023003089A patent/CL2023003089A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501246A5 (enExample) | ||
| US20230181698A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| JP7590015B2 (ja) | 低抗原性細胞の製造方法 | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| JP2024500858A5 (enExample) | ||
| JP2022512703A5 (enExample) | ||
| JP2021518160A5 (enExample) | ||
| JP2022524212A (ja) | 操作されたｍＲＮＡ配列及びその使用 | |
| JP2024520528A5 (enExample) | ||
| WO2023115732A1 (en) | Single-pot methods for producing circular rnas | |
| JP2018011597A (ja) | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 | |
| JP2018510219A (ja) | Ｔａｔ誘導性ｃｒｉｓｐｒ／エンドヌクレアーゼに基づく遺伝子編集 | |
| WO2017075451A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| JP2021519587A5 (enExample) | ||
| US20250144149A1 (en) | Adenosine deaminase base editors and methods for use thereof | |
| JP2024506016A (ja) | 免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法 | |
| EP4646482A2 (en) | Genome editing compositions and methods of use | |
| WO2021212123A1 (en) | Fusion proteins of ctl antigens for treating melanoma | |
| US20240307444A1 (en) | Methods and compositions for improved immunotherapies | |
| JP2024528967A5 (enExample) | ||
| JP2009536922A (ja) | ウイルスに特異的な可溶性ｔ細胞受容体組成物 | |
| Gim et al. | Identification and expression analyses of equine endogenous retroviruses in horses | |
| EP3165605B1 (en) | TCR cDNA AMPLIFICATION METHOD | |
| JP2024534639A5 (enExample) | ||
| CN115667288A (zh) | 抗原池 |